张晓辉，ac米兰官方网站系统医学研究院研究员，ac米兰官方网站博士生导师，助理教授。江苏省双创人才，姑苏创新领军人才。主要从事面向遗传病治疗的碱基编辑技术研究，包括基因编辑工具的开发、优化以及在疾病动物模型和基因治疗方面的应用。获得国家自然科学基金青年科学基金项目（B类和C类）以及国家重点研发计划等项目资助。
      院校引进人才，2022年加入院校。曾于2020年博士毕业后受聘华东师范大学生命科学学院副研究员，从事基因编辑工具的开发、优化以及在疾病动物模型和基因治疗方面的应用。

60%左右遗传病是基因点突变所致。新一代基因编辑技术-碱基编辑技术，以优于传统技术的效率与安全性，成为纠正致病点突变的最佳工具。课题组长期从事碱基编辑技术研究，包括基因编辑工具的开发、优化以及在疾病动物模型和基因治疗方面的应用。
     近期取得如下进展：1)率先创建双功能碱基编辑器，突破底物单一限制；2）创建高效、靶向范围广的系列新型碱基编辑器，突破效率和靶向范围限制；3）创建多款高精准碱基编辑器，解决精度不足和脱靶风险；并证明这些新型碱基编辑器在β-地贫治疗、动物模型制作等具有广泛应用前景。相关研究成果以第一/通讯作者在Nature Biotechnology, Nature Cell Biology, Nature Chemical Biology和Nature Communications等学术期刊上发表论文20余篇，授权专利12项。

1. Jingxuan Ren#, Jiawei Yao#, Qiuyu Cao#, Yinuo Li#, Yang Li#, Ziyi Zhang, Xiyu Ge, Shengfang Wang, Yang Zhang*, Xiaogang Wang*, Xiaohui Zhang*, Protein-nucleic acid language model-assisted design of precise and compact adenine base editor. Nature Communication, DOl:10.1038/s41467-025-65311-z3.(2025). (IF=15.7)

2. Mengyu Shang#, Yinuo Li#, Qiuyu Cao#, Jingxuan Ren#, Yuqiang Zeng, Jinxin Wang, Rachel V. L. Gonzalez, Xiaohui Zhang*. A motif preferred adenine base editor with minimal bystander and off-targets editing. Nature Communications 16, 9153 (2025). (IF=15.7)

3. Niannian Xue#, Xu Liu#, Dan Zhang#, Youming Wu#, Yi Zhong, Jinxin Wang, Wenjing Fan, Haixia Jiang, Biyun Zhu, Xiyu Ge, Rachel V L Gonzalez, Liang Chen, Shun Zhang, Peilu She, Zhilin Zhong, Jianjian Sun, Xi Chen, Liren Wang, Zhimin Gu, Ping Zhu, Mingyao Liu, Dali Li*, Tao P Zhong*, Xiaohui Zhang*. Improving adenine and dual base editors through introduction of TadA-8e and Rad51DBD. Nature Communications 14, 1224 (2023). (IF=14.7)

4. Liang Chen#, Shun Zhang#, Niannian Xue#, Mengjia Hong#, Xiaohui Zhang#, Dan Zhang, Jing Yang, Sijia Bai, Yifan Huang, Haowei Meng, Hao Wu, Changming Luan, Biyun Zhu, Gaomeng Ru, Hongyi Gao, Liping Zhong, Meizhen Liu, Mingyao Liu, Yiyun Cheng, Chengqi Yi, Liren Wang, Yongxiang Zhao*, Gaojie Song*, Dali Li*. Engineering a precise adenine base editor with minimal bystander editing. Nature Chemical Biology 19, 101–110 (2022) (IF=14.8)

5. Xiaohui Zhang#, Biyun Zhu#, Liang Chen#, Ling Xie, Weishi Yu, Ying Wang, Linxi Li, Shuming Yin, Lei Yang, Handan Hu, Honghui Han, Yongmei Li, Liren Wang, Geng Chen, Xueyun Ma, Hongquan Geng, Wanfeng Huang, Xiufeng Pang, Zuozhen Yang, Yuxuan Wu, Stefan Siwko, Ryo Kurita, Yukio Nakamura, Li Yang, Mingyao Liu, Dali Li*. A Dual base editor catalyzes both cytosine and adenine base conversions in human cells. Nature Biotechnology 38, 856–860 (2020). (Highlighted by Nature Reviews Genetics). (IF=37, ESI 1%, C100)

6. Xiaohui Zhang#, Liang Chen#, Biyun Zhu#, Liren Wang, Caiyu Chen, Mengjia Hong, Yifan Huang, Huiying Li, Honghui Han, Bailian Cai, Weishi Yu, Shuming Yin, Lei Yang, Zuozhen Yang, Meizhen Liu, Ying Zhang, Zhiyong Mao, Yuxuan Wu, Mingyao Liu, Dali Li*. Increasing the efficiency and targeting range of cytidine base editors through fusion of a single-stranded DNA-binding protein domain. Nature Cell Biology 22, 740–750 (2020) (Highlighted by Nature Cell Biology). (IF=28, ESI 1%, C100)

7. Lei Yang#, Xiaohui Zhang#, Liren Wang#, Shuming Yin#, Biyun Zhu, Ling Xie, Qiuhui Duan, Huiqiong Hu, Rui Zheng, Yu Wei, Liangyue Peng, Honghui Han, Jiqin Zhang, Wenjuan Qiu, Hongquan Geng, Stefan Siwko, Xueli Zhang, Mingyao Liu, Dali Li*. Increasing targeting scope of adenosine base editors in mouse and rat embryos through fusion of TadA deaminase with Cas9 variants. Protein & Cell 9, 814-819 (2018) (Cover story, Highlight by Protein & Cell). (IF=12.8)

8. Xiaohui Zhang#, Liren Wang#, Mingyao Liu* and Dali Li*. CRISPR/Cas9 system: a powerful technology for in vivo and ex vivo gene therapy. Science China Life Science 60(5):468-475 (2017). (IF=9.5)

9. Xiaohui Zhang#, Louis Y Tee, Xiaogang Wang, Qunshan Huang and Shihua Yang*. Off-target effects in CRISPR/Cas9-mediated genome engineering. Molecular Therapy-Nucleic Acids 4, e264 (2015). (IF=5.0, ESI 1%, C100)